Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Articles / Jul / Nano-Origami Versus Infectious Agents
Discovery & Development Drug Discovery Research News

Nano-Origami Versus Infectious Agents

A team of researchers in Munich have found a way to trap viruses inside man-made nanomaterials

By Angus Stewart 07/31/2021 1 min read

Share

It was by serendipity that Hendrik Dietz, Professor of Biomolecular Nanotechnology at the Physics Department of the Technical University of Munich, and his team of scientists learned how to make a virus trap (1).

“We were working on building virus-sized icosahedral shells for several years (1, 2), and also on ways to produce many such objects (3)” says Dietz. “In summer 2019, I started thinking about applications and, well, it occurred to me: now that these things are virus-sized… how about putting viruses inside? And so we started testing this idea…”

The virus traps use nanocapsules to engulf and neutralize viruses – and have been tested successfully against hepatitis and adeno-associated viruses in cell cultures. Depending on the details of the trap design, they were able to reduce the activity of these viruses almost completely. Dietz hopes that the method could become a cheap, programmable, and mass-producible mechanical antiviral drug. Such a drug may prove very valuable, since the vast majority of viral diseases have no cure whatsoever.

He also provided a helpful “recipe” for the traps:

  1. Make two virus-sized half-shells. These are made by programmable self-assembly with DNA origami.
  2. Coat the interior of the half-shells with molecules that have an affinity for virus surface features, such as antibodies, peptides, or host receptor domains.
  3. Add to virus! The virus will be sequestered by the shells like flies on flypaper. The virus is now encased and can no longer interact with cells.

Although the work began pre-pandemic, it’s possible that the virus traps could also work against coronaviruses. Dietz and his team hope that their approach will reduce viral load in acute infections, offering a therapeutic benefit. The next step is to test the work in mice. Also on Dietz’s agenda are the production of broad-spectrum shells with coatings that will stick to many viruses and virucidal shells that feature enzymes capable of degrading a virus’ surface and rendering it harmless.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. 1. H Dietz et al., Nature Methods (2021). DOI: 10.1038/s41563-021-01020-4
  2. 2. H Dietz et al, Nature (2017). DOI 10.1038/nature24651
  3. 3. Praetorius et al, Nature (2017). 10.1038/nature24650

About the Author(s)

Angus Stewart

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.

More Articles by Angus Stewart

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.